Cancer of unknown primary origin

Cancer of unknown primary origin
Cancer of unknown primary origin
Other names	Occult cancer
Specialty	Oncology

Last updated December 09, 2023

Cancer of unknown primary origin (CUP) is a cancer that is determined to be at the metastatic stage at the time of diagnosis, but a primary tumor cannot be identified. A diagnosis of CUP requires a clinical picture consistent with metastatic disease and one or more biopsy results inconsistent with a tumor cancer

Signs and symptoms

Most cancers typically present as a single primary tumor. Over the course of time—particularly if the primary tumor is left untreated—smaller "satellite" tumors will appear at other places in the body, a phenomenon known as metastasis. Less commonly, a metastatic tumor is found first; but in most such cases, the primary tumor can then be located via examination and testing. Rarely (3–5% of the time), the primary tumor cannot be found because it is too small, or because it has regressed due to immune system activity or other factors. In such situations a diagnosis of cancer of unknown primary origin (CUP) is made.

CUP usually comes to attention because of masses or swellings found somewhere in the body, either by physical examination or on medical imaging performed for another indication.^{[ citation needed ]} The disease typically develops rapidly, and metastases may occur in places in the body that are otherwise unusual.^[2] Comprehensive physical examination is part of the process to identify a possible primary source of cancer; this should include the breasts, lymph nodes, the skin, external genitals, as well as an internal examination of the rectum and of the pelvic organs.^[3]

The location of metastases may be a clue as to the underlying source, even if this cannot be found on investigations. For instance, a woman in whom there is axillary lymphadenopathy (swelling in the lymph nodes of the armpit) it is likely that the cancer originated in the breast, and men with lymph node deposits in the mediastinum of the chest and/or retroperitoneal space of the abdomen may have a germ cell tumor.^[2]

Mechanism

Cancer of unknown primary source is not a single type of cancer, although researchers have attempted to find a common characteristic that explains why a cancer might spread very early without causing symptoms at the site of origin.^[2] It is generally accepted that cancer of unknown primary site exists because the primary tumor is not identified due to clinical or technological inefficiencies, or because the primary tumor regresses or stays dormant after spreading the cancer cells that generate the metastases. This view is widely accepted in oncology; in fact, these cancers are also referred to as occult primary tumors. Because the site of the primary tumor usually dictates the treatment and expected outcome, this view may help create uncertainty and anxiety among health professionals and patients, who may feel that their evaluation has been incomplete.^{[ medical citation needed ]}

Because stem cells have a natural ability to migrate and also play a key role in cancer development, it has been proposed that a cancer of unknown primary site may form when deregulated, premalignant or cancerous stem cells migrate away from their natural tissue and give rise to a cancer in the new site before or without generating a tumor in their original tissue.^[4] Forming a tumor in a tissue is not a prerequisite for stem cells to move away from that tissue. Stem cells can migrate from their natural tissue and initiate a cancer in the new site before generating a detectable tumor in their natural tissue. In this case, the primary tumor could be identified after some time. However, stem cells can also migrate away from their natural tissue without generating a cancer there. In this case, the "primary tumor" would never exist (see Figure). This can explain why the primary site is not identified even on postmortem examination in many patients with these cancers.^[4] This view of CUP may provide relief to health professionals and patients. After a detailed imaging and pathologic analysis, oncologists can tell their patients with CUP that metastasis does not always involve the formation of a primary tumor, and that their diagnostic evaluation is complete.^[4]

Diagnosis

In recent years, microscopic and other diagnostic techniques have improved dramatically. However, the tissue of origin can be still determined only about in one in four cases of CUPs with these methods.^[5] In some cases, the part of the body where cancer cells are first discovered helps the doctor decide which diagnostic tests will be most helpful. Additional clues which may be helpful in determining the primary site include the pattern of spread, and the cell type, which is based on its appearance under a microscope (histology).^{[ medical citation needed ]}

The initial work-up of a cancer of unknown primary includes a CT scan of the chest, abdomen, and pelvis, with IV contrast.^[5] Women with enlarged lymph nodes (lymphadenopathy) confined to the axillary region with CUP should have a mammogram or ultrasound to evaluate for possible breast cancer. If those imaging studies are normal, then an MRI of the breast may be appropriate.^[5] A PET CT scan should be done for squamous cell carcinoma involving lymph nodes of the neck region.^[5] For other types of cancer of unknown primary, a PET-CT offers uncertain benefit.^[5]

The pattern of spread may suggest the location of the primary site. For example, metastatic cancer found in the upper body is more likely to have an origin above the diaphragm, at sites such as the lung and breast. If the metastatic cancer appears first in the lower part of the body, the primary cancer is more likely to be at sites below the diaphragm, such as the pancreas and liver.^{[ medical citation needed ]}

When the cancer cells are poorly differentiated (that is, they look less evolved than normal cells when viewed under a microscope), the cancer may be either a lymphoma or a germ cell tumor. Lymphomas begin in the lymphatic system. Germ cell tumors usually begin in the ovaries and testes. In patients in whom the primary cancer is eventually found, the lung and pancreas are the most common primary cancer sites. CUP also may be traced to the breast, prostate, colon, or rectum as the primary site.^{[ medical citation needed ]}

Sometimes, however, even when doctors use very sophisticated methods to try to identify the primary site, the part of the body the cancer cells came from cannot be determined. About 2 to 4 percent of all cancer patients have a cancer whose primary site is never found. Identifying the primary tumor site is important because knowing its location and type often helps doctors plan the best treatment. Treatment that is specific to the suspected type of cancer is likely to be more effective. Still, when diagnostic tests have not identified the primary site, doctors must decide whether the potential benefits of more extensive testing outweigh a patient's discomfort, possible complications, and the financial costs.^{[ medical citation needed ]}

Immunohistochemical testing

Antibodies may be used to determine the expression of protein markers on the surface of cancer cells. Often the expression of these antigens is similar to the tissue that the cancer grew from, so immunohistochemical testing sometimes helps to identify the source of the cancer. Individual tests often do not provide definitive answers, but sometimes patterns may be observed, suggesting a particular site of origin (e.g. lung, colon, etc.). Immunohistochemical testing suggests a single source of cancer origin in about one in four cases of CUP.^[5] However, there is a lack of definitive research data showing that treatment guided by information from immunohistochemical testing improves outcomes or long-term prognosis.^{[ medical citation needed ]}

Classification

CUP may be classified by its appearance under a light microscope. The majority of cancers of unknown primary, about 90%, are adenocarcinomas, with 60% appearing as moderately to well-differentiated adenocarcinoma, while about 30% are poorly differentiated adenocarcinoma. The term adenocarcinoma refers to cancer that begins in the cells in glandular structures in the lining or covering of certain organs in the body. Common primary sites for adenocarcinomas include the lung, pancreas, breast, prostate, stomach, liver, and colon.^{[ medical citation needed ]}

The remaining 10 percent are either poorly or undifferentiated malignant neoplasms (5%), or squamous cell carcinomas (5%).^[5] Rarely, CUP may appear as neuroendocrine tumors, or mixed tumors, such as sarcomatoid, basaloid, or adenosquamous carcinomas.^{[ medical citation needed ]}

Management

Because CUP refers to many different cancers, treatment depends on where the cancer is found, the microscopic appearance of the cancer cells, the biochemical characterization of the cells, and the patient's age and overall physical condition. In women, who present with axillary lymph node involvement, treatment is offered along the lines of breast cancer. In patients, who have neck lymph node involvement, then treatment is offered along the lines of head and neck cancer. If inguinal lymph nodes are involved, then treatment may be offered along the lines of genitourinary cancer.^{[ citation needed ]}

If the site of origin is unknown or undiscovered, then the histology of the tumor (e.g., adenocarcinoma, squamous cell or mesenchymal) can usually be identified, and a probable origin may be assumed. When this is possible, then treatment is based on the type of cell and probable origin.^[6] Based on histological subtype, combination chemotherapy may be selected. A combination of carboplatin and paclitaxel is often used. Advances techniques such as FISH and tissue of origin testing may also be employed. Germ cell tumors often carry abnormality of chromosome 12, which if identified, directs treatment for metastatic germ cell tumors.^{[ medical citation needed ]}

No method is standard for all forms of CUP, but chemotherapy, radiation therapy, hormone therapy, and surgery may be used alone or in combination to treat patients who have CUP. Even when the cancer is unlikely to be cured, treatment may help the patient live longer or improve the patient's quality of life. Radiation may be used to shrink a variety of local tumors.^[6] However, the potential side effects of the treatment must be considered along with the potential benefits. In CUP to secondary neck nodes, surgery followed by external beam radiotherapy is sufficient.^[7] For CUP with an unfavorable prognosis, treatment with taxanes may provide a slight survival benefit.^[8] The uncertainties and ambiguity inherent in a CUP diagnosis may cause additional stress for the patient.^[6]

Prognosis

Most people with cancer of unknown primary origin have widely disseminated and incurable disease, although a few can be cured through treatment. With treatment, typical survival with CUP ranges from 6 to 16 months.^[5] Survival rates are lower in cases with visceral metastatic disease, ranging from 6 to 9 months.^[5] Survival rates are higher when the cancer is more limited to lymph nodes, pleura, or peritoneal metastasis, which ranges from 14 to 16 months.^[5] Long-term prognosis is somewhat better if a particular source of cancer is strongly suggested by clinical evidence.^[5]

Epidemiology

CUP sometimes runs in families.^[6] It has been associated with familial lung, kidney, and colorectal cancers, which suggests that these sites may often be the origin of unidentifiable CUP cancers.^[6]

UK

Around 9,800 people were diagnosed with cancer of unknown primary in the UK in 2011, and around 10,625 people died from the disease in 2012.^[9]

History

From 1980 to 1990, definition of unknown primary cancer was based on imaging results.^[5] Subsequently, research on immunohistochemistry allowed for the classification of cancer of unknown primary into sub-types. From 2000 to 2010, tailored therapies began to evolve, targeting specific subtypes of unknown primary.^[5]

Related Research Articles

Metastasis is a pathogenic agent's spread from an initial or primary site to a different or secondary site within the host's body; the term is typically used when referring to metastasis by a cancerous tumor. The newly pathological sites, then, are metastases (mets). It is generally distinguished from cancer invasion, which is the direct extension and penetration by cancer cells into neighboring tissues.

A Krukenberg tumor refers to a malignancy in the ovary that metastasized from a primary site, classically the gastrointestinal tract, although it can arise in other tissues such as the breast. Gastric adenocarcinoma, especially at the pylorus, is the most common source. Krukenberg tumors are often found in both ovaries, consistent with its metastatic nature.

Carcinoma is a malignancy that develops from epithelial cells. Specifically, a carcinoma is a cancer that begins in a tissue that lines the inner or outer surfaces of the body, and that arises from cells originating in the endodermal, mesodermal or ectodermal germ layer during embryogenesis.

Testicular cancer is cancer that develops in the testicles, a part of the male reproductive system. Symptoms may include a lump in the testicle or swelling or pain in the scrotum. Treatment may result in infertility.

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. RCC occurrence shows a male predominance over women with a ratio of 1.5:1. RCC most commonly occurs between 6th and 7th decade of life.

Ovarian cancer is a cancerous tumor of an ovary. It may originate from the ovary itself or more commonly from communicating nearby structures such as fallopian tubes or the inner lining of the abdomen. The ovary is made up of three different cell types including epithelial cells, germ cells, and stromal cells. When these cells become abnormal, they have the ability to divide and form tumors. These cells can also invade or spread to other parts of the body. When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses. These symptoms may include bloating, vaginal bleeding, pelvic pain, abdominal swelling, constipation, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver.

Anal cancer is a cancer which arises from the anus, the distal opening of the gastrointestinal tract. Symptoms may include bleeding from the anus or a lump near the anus. Other symptoms may include pain, itchiness, or discharge from the anus. A change in bowel movements may also occur.

Lumpectomy is a surgical removal of a discrete portion or "lump" of breast tissue, usually in the treatment of a malignant tumor or breast cancer. It is considered a viable breast conservation therapy, as the amount of tissue removed is limited compared to a full-breast mastectomy, and thus may have physical and emotional advantages over more disfiguring treatment. Sometimes a lumpectomy may be used to either confirm or rule out that cancer has actually been detected. A lumpectomy is usually recommended to patients whose cancer has been detected early and who do not have enlarged tumors. Although a lumpectomy is used to allow for most of the breast to remain intact, the procedure may result in adverse affects that can include sensitivity and result in scar tissue, pain, and possible disfiguration of the breast if the lump taken out is significant. According to National Comprehensive Cancer Network guidelines, lumpectomy may be performed for ductal carcinoma in situ (DCIS), invasive ductal carcinoma, or other conditions.

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

An anal sac adenocarcinoma is an uncommon and aggressive malignant tumor found in dogs that arises from the apocrine glandular tissue of anal sac. The disease exists in cats as well, but is much less common in that species. They are the second most common cancerous cause of hypercalcaemia in dogs, following T-cell lymphoma.

Papillary thyroid cancer is the most common type of thyroid cancer, representing 75 percent to 85 percent of all thyroid cancer cases. It occurs more frequently in women and presents in the 20–55 year age group. It is also the predominant cancer type in children with thyroid cancer, and in patients with thyroid cancer who have had previous radiation to the head and neck. It is often well-differentiated, slow-growing, and localized, although it can metastasize.

Vaginal cancer is an extraordinarily rare form of cancer that develops in the tissue of the vagina. Primary vaginal cancer originates from the vaginal tissue – most frequently squamous cell carcinoma, but primary vaginal adenocarcinoma, sarcoma, and melanoma have also been reported – while secondary vaginal cancer involves the metastasis of a cancer that originated in a different part of the body. Secondary vaginal cancer is more common. Signs of vaginal cancer may include abnormal vaginal bleeding, dysuria, tenesmus, or pelvic pain, though as many as 20% of women diagnosed with vaginal cancer are asymptomatic at the time of diagnosis. Vaginal cancer occurs more frequently in women over age 50, and the mean age of diagnosis of vaginal cancer is 60 years. It often can be cured if found and treated in early stages. Surgery alone or surgery combined with pelvic radiation is typically used to treat vaginal cancer.

Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy and systemic treatment. Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.

Metaplastic carcinoma, otherwise known as metaplastic carcinoma of the breast (MCB), is a heterogeneous group of cancers that exhibit varied patterns of metaplasia and differentiation along multiple cell lines. This rare and aggressive form of breast cancer is characterized as being composed of a mixed group of neoplasms containing both glandular and non-glandular patterns with epithelial and/or mesenchymal components. It accounts for fewer than 1% of all breast cancer diagnoses. It is most closely associated with invasive ductal carcinoma of no special type. (IDC), and shares similar treatment approaches. Relative to IDC, MCB generally has higher histological grade and larger tumor size at time of diagnosis, with a lower incidence of axillary lymph node involvement. MCB tumors are typically estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor-2 (HER-2) negative, meaning hormone therapy is generally not an effective treatment option, which correlates to a relatively poor prognosis. MCB was first recognized as a distinct pathological entity in 2000 by the World Health Organization.

Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated.

Metastatic breast cancer, also referred to as metastases, advanced breast cancer, secondary tumors, secondaries or stage IV breast cancer, is a stage of breast cancer where the breast cancer cells have spread to distant sites beyond the axillary lymph nodes. There is no cure for metastatic breast cancer; there is no stage after IV.

Spiradenomas (SA) are rare, benign cutaneous adnexal tumors that may progress to become their malignant counterparts, i.e. spiradenocarcinomas (SAC). Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. SA and SAC tumors were regarded as eccrine gland tumors and termed eccrine spiradenomas and eccrine spiradenocarcinomas, respectively. However, more recent studies have found them to be hair follicle tumors and commonly term them spiradenomas and spiradenocarcinomas, respectively. Further confusing the situation, SA-like and SAC-like tumors are also 1) manifestations of the inherited disorder, CYLD cutaneous syndrome (CCS), and 2) have repeatedly been confused with an entirely different tumor, adenoid cystic carcinomas of the salivary gland. Here, SA and SAC are strictly defined as sporadic hair follicle tumors that do not include the hereditary CCS spiradenomas and heridtary spiradenocarcinoms of CCS or the adenoid cystic carcinomas.

Neuroendocrine carcinoma of the cervix is best defined separately:Neuroendocrine: Of, relating to, or involving the interaction between the nervous system and the hormones of the endocrine glands.Carcinoma: An invasive malignant tumor derived from epithelial tissue that tends to metastasize to other areas of the body.

Carcinoma of the tonsil is a type of squamous cell carcinoma. The tonsil is the most common site of squamous cell carcinoma in the oropharynx. It comprises 23.1% of all malignancies of the oropharynx. The tumors frequently present at advanced stages, and around 70% of patients present with metastasis to the cervical lymph nodes. . The most reported complaints include sore throat, otalgia or dysphagia. Some patients may complain of feeling the presence of a lump in the throat. Approximately 20% patients present with a node in the neck as the only symptom.

Mammary secretory carcinoma (MSC), also termed secretory carcinoma of the breast, is a rare form of the breast cancers. MSC usually affects women but in a significant percentage of cases also occurs in men and children. Indeed, McDvitt and Stewart first described MSC in 1966 and termed it juvenile breast carcinoma because an increased number of cases were at that time diagnosed in juvenile females. MSC is the most common form of breast cancer in children, representing 80% of childhood breast cancers, although it accounts for less than 0.15% of all breast cancers.

References

1 2 Stella, GM; Senetta, R; Cassenti, A; Ronco, M; Cassoni, P (24 January 2012). "Cancers of unknown primary origin: current perspectives and future therapeutic strategies". Journal of Translational Medicine. 10: 12. doi: 10.1186/1479-5876-10-12 . PMC 3315427 . PMID 22272606.
1 2 3 Pavlidis N, Pentheroudakis G (April 2012). "Cancer of unknown primary site". Lancet. 379 (9824): 1428–35. doi:10.1016/S0140-6736(11)61178-1. PMID 22414598. S2CID 44385281.
↑ National Institute for Health and Clinical Excellence . Clinical guideline 104: Metastatic malignant disease of unknown primary origin . London, 2010.
1 2 3 López-Lázaro (1 May 2015). "The migration ability of stem cells can explain the existence of cancer of unknown primary site. Rethinking metastasis". Oncoscience. 2 (5): 467–75. doi:10.18632/oncoscience.159. PMC 4468332 . PMID 26097879.
1 2 3 4 5 6 7 8 9 10 11 12 13 Varadhachary, Gauri R.; Raber, Martin N. (21 August 2014). "Cancer of Unknown Primary Site". New England Journal of Medicine. 371 (8): 757–765. CiteSeerX 10.1.1.1019.2799 . doi:10.1056/NEJMra1303917. PMID 25140961.
1 2 3 4 5 Ettinger, David S.; Agulnik, Mark; Cates, Justin M. M.; Cristea, Mihaela (December 2011). "Occult primary". Journal of the National Comprehensive Cancer Network. 9 (12): 1358–1395. doi: 10.6004/jnccn.2011.0117 . ISSN 1540-1413. PMID 22157556.
↑ Krishnatreya M, Sharma JD, Kataki AC, Kalita M (2014). "Survival in carcinoma of unknown primary to neck nodes treated with neck dissection and radiotherapy". Annals of Medical and Health Sciences Research. 4 (Suppl 2): S165–S6. doi: 10.4103/2141-9248.138050 . PMC 4145520 . PMID 25184090.
↑ Lee, J.; Hahn, S.; Kim, D.-W.; Kim, J.; Kang, S. N.; Rha, S. Y.; Lee, K. B.; Kang, J.-H.; Park, B.-J. (Jan 15, 2013). "Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis". British Journal of Cancer. 108 (1): 39–48. doi:10.1038/bjc.2012.516. ISSN 1532-1827. PMC 3553519 . PMID 23175147.
↑ "Cancer of unknown primary statistics". Cancer Research UK. Retrieved 27 October 2014.

External links

med/1463 at eMedicine
Clinically reviewed information on unknown primary cancer for patients, from Cancer Research UK
The CUP Foundation – Jo's Friends – UK-based information and support for patients with CUP.
Cancer.Net: Unknown Primary Cancer

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[Stella-1] 1 2 Stella, GM; Senetta, R; Cassenti, A; Ronco, M; Cassoni, P (24 January 2012). "Cancers of unknown primary origin: current perspectives and future therapeutic strategies". Journal of Translational Medicine. 10: 12. doi: 10.1186/1479-5876-10-12 . PMC 3315427 . PMID 22272606.

[Pavlidis2012-2] 1 2 3 Pavlidis N, Pentheroudakis G (April 2012). "Cancer of unknown primary site". Lancet. 379 (9824): 1428–35. doi:10.1016/S0140-6736(11)61178-1. PMID 22414598. S2CID 44385281.

[NICE2010-3] National Institute for Health and Clinical Excellence . Clinical guideline 104: Metastatic malignant disease of unknown primary origin . London, 2010.

[LopezLarazo2015-4] 1 2 3 López-Lázaro (1 May 2015). "The migration ability of stem cells can explain the existence of cancer of unknown primary site. Rethinking metastasis". Oncoscience. 2 (5): 467–75. doi:10.18632/oncoscience.159. PMC 4468332 . PMID 26097879.

[Varadhachary-5] 1 2 3 4 5 6 7 8 9 10 11 12 13 Varadhachary, Gauri R.; Raber, Martin N. (21 August 2014). "Cancer of Unknown Primary Site". New England Journal of Medicine. 371 (8): 757–765. CiteSeerX 10.1.1.1019.2799 . doi:10.1056/NEJMra1303917. PMID 25140961.

[:0-6] 1 2 3 4 5 Ettinger, David S.; Agulnik, Mark; Cates, Justin M. M.; Cristea, Mihaela (December 2011). "Occult primary". Journal of the National Comprehensive Cancer Network. 9 (12): 1358–1395. doi: 10.6004/jnccn.2011.0117 . ISSN 1540-1413. PMID 22157556.

[7] Krishnatreya M, Sharma JD, Kataki AC, Kalita M (2014). "Survival in carcinoma of unknown primary to neck nodes treated with neck dissection and radiotherapy". Annals of Medical and Health Sciences Research. 4 (Suppl 2): S165–S6. doi: 10.4103/2141-9248.138050 . PMC 4145520 . PMID 25184090.

[8] Lee, J.; Hahn, S.; Kim, D.-W.; Kim, J.; Kang, S. N.; Rha, S. Y.; Lee, K. B.; Kang, J.-H.; Park, B.-J. (Jan 15, 2013). "Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis". British Journal of Cancer. 108 (1): 39–48. doi:10.1038/bjc.2012.516. ISSN 1532-1827. PMC 3553519 . PMID 23175147.

[9] "Cancer of unknown primary statistics". Cancer Research UK. Retrieved 27 October 2014.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]